Shire/Actelion rumors highlight M&A buzz in orphan space
This article was originally published in Scrip
Reports of a £12.4bn ($18.9bn) preliminary approach sent Shire's share price down by 2.75% to £53.05 on the London Stock Exchange on 8 June, while Actelion's stock rose nearly 10% to an all-time high of CHF144.50 on the Swiss exchange, pushing its market capitalization up to CHF16.5bn ($17.5bn).
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.